Prospective, randomized, multi-center, open label phase III study to evaluate the efficacy and safety of immunosuppression following a heart-beating cadaveric renal transplantation based on the use of rabbit anti-T-lymphocyte serum, tacrolimus and mycophenolate, free of concomitant corticosteroids from the start of immunosuppression - IBERICA

Fresenius Biotech GmbH0 个研究点目标入组 160 人开始时间: 2006年5月25日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Patients will be enrolled in this study only if they meet all of the following criteria:
•Signed and dated informed consent form.
•End-stage renal disease.
•Candidates for a first transplantation. Re-transplant patients are eligible if a graft loss after transplantation was NOT due to immunological reasons.
•Availability of a heart-beating cadaveric donor up to 70 years of age with a cold ischemia time < 36 hours.
•Male or female patients between 18 to 75 years of age (inclusive).
•Patients able to comply with all study related requirements.
•Patients able to receive oral medication.
•Women of childbearing age with a safe contraceptive method throughout the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Patients will not be enrolled in this study if they meet any of the following criteria:
•Women who are pregnant or breast feeding.
•Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection (patients and respective donors).
•Severe actual viral, bacterial or fungal infection not adequately controlled.
•Patients with anamnestically known hypersensitivity to rabbit immunoglobulin antibodies or positive rabbit immunoglobulin skin test or known allergies to any component of the immunosuppressive drugs per protocol.
•Patients at high immunological risk defined as current PRA = 25% or historical PRA = 50%.
•Patients receiving pre-transplant immunosuppressive treatment, including corticosteroids.
•Patients with current or history of malignancies (exception basal cell carcinoma or squamous cell carcinoma in remission).
•Patients with previous transplantation except 1st graft loss due to surgical complications.
•Patients receiving combined transplantation.
•Patients with major organ dysfunctions.
•Serious psychiatric or psychological disorders.
•Pre-transplant thrombocytopenia: < 50,000 thrombocytes/µl.
•Pre-transplant leukopenia: < 2,000 leukocytes/µl.
•Unable or unwilling to comply fully with the protocol.
•Participation in another study of an investigational medicinal product concurrently or within the last 30 days.

发起方

Fresenius Biotech GmbH